Logo

Genomic Profiling Systems Awarded Biowarfare SBIR

May 19, 2003

NEW YORK, May 19 - Bedford, Mass.-based diagnostic firm Genomic Profiling Systems has received a $119,820 Phase I Small Business Innovation Research Grant from the National Institutes of Health to develop its MultiPath test for the rapid detection of biological warfare agents, the company said today.

 

The grant, awarded by the National Institute of Allergy and Infectious Disease, will support commercializaton of the company's technology, which uses high-intensity, target-specific microbead labels in combination with instant film imaging. According to the company, individual microbial cells labeled with the beads are easily visible on instant film.

 

The company said that a commercial version of the quantitative test would be able to scan for agents such as anthrax, smallpox, and botulinum toxin at levels below what other rapid test methods detect.

Breaking News
The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.